Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib

NCT00522145 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT00522145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
February 28, 2010
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung